BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 26, 2014
View Archived Issues
Ignyta reports preliminary data from phase I/II trial of anticancer candidate
Read More
Merck KGaA synthesizes new agents that act as SYK inhibitors
Read More
Reata studies RTA-408 to treat ocular pain and inflammation following ocular surgery
Read More
InterMune reports data from phase III ASCEND trial in idiopathic pulmonary fibrosis
Read More
Potential antidiabetic strategy: synergistic effects of GPR40 agonist and DPP IV inhibitor
Read More
PMV Pharma and Chiromics form drug discovery collaboration
Read More
ImmunoCellular Therapeutics receives orphan drug status in Europe for ICT-107 in glioblastoma
Read More
Verastem acquires rights to cancer stem cell inhibitor VS-4718
Read More
Myalept obtains FDA approval for rare metabolic disease
Read More
FDA accepts filing of peramivir NDA
Read More
rEVO Biologics submits IND to FDA for ATryn in preeclampsia
Read More
Lilly's once-weekly dulaglutide shows non-inferiority to liraglutide in head-to-head trial
Read More
Neuroprotection seen with imatinib in stroke model
Read More
Neovacs focuses on four therapeutic areas
Read More
New HIV attachment inhibitors designed at Bristol-Myers Squibb
Read More
Janssen R&D Ireland patents novel Fabl inhibitors
Read More
Synchroneuron begins dosing in phase II study of SNC-102 for tardive dyskinesia
Read More
Humanetics and USAMRICD enter into CRADA to study BIO-300 to treat phosgene exposure
Read More
Dyax reports results from phase Ia study of DX-2930 for prevention of HAE attacks
Read More
Roche synthesizes new modulators of neurogenesis
Read More
European approval for Mirvaso for facial erythema of rosacea
Read More
RPC-1063 demonstrates favorable safety and PK profiles in healthy subjects
Read More
aTyr Pharma completes enrollment in phase I trial of Resokine
Read More
Artery Therapeutics presents novel ApoE mimetic peptides with antidiabetic activity
Read More
Pierre Fabre researchers prepare new griseofulvin derivatives for cancer
Read More